Regulation of [3H]dopamine release from guinea pig striatum by NMDA receptor/channel activators and inhibitors.
Excitatory amino acids, that interact with the N-methyl-D-aspartate (NMDA) receptor stimulate release of [3H]dopamine [3H]DA) from the striatum of the guinea pig and rat in a concentration-dependent manner. DA release was measured in the presence of domperidone and nomifensine to avoid complications associated with autoreceptor alteration of and reuptake of released DA. This release is inhibited by magnesium. Therefore, all experiments were performed in the absence of this ion. The competitive NMDA antagonists D-(-)2-amino-5-phosphonopentanoic acid and 3-[(+-)-2-carboxypiperazin-4-yl]-propyl-1-phosphonic acid and the noncompetitive antagonists (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine and phencyclidine also inhibit NMDA-stimulated release. Glycine enhances NMDA-stimulated release and can release [3H]DA in the absence of added NMDA. Release stimulated by glycine alone is not affected by 3-[(+-)-2-carboxypiperazine-4-yl]-propyl-1-phosphonic acid. Conversely, if the glycine antagonist 3-amino-1-hydroxy-2-pyrrolidone or 6-cyano-7-nitroquinoxaline-2,3-dione is included, NMDA elicits less release of [3H]DA. This inhibition can be overcome by increasing the concentration of glycine. The kappa-selective opioid agonist trans-(+-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl]-benzene-acetamide is also capable of inhibiting the NMDA-stimulated release of [3H]DA from guinea pig and rat striatum.(ABSTRACT TRUNCATED AT 250 WORDS)
Werling
L L
LL
Department of Pharmacology, Uniformed Services University, Bethesda, Maryland.
Jacocks
H M
HM
McMahon
P N
PN
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D005998:Glycine / Q000494:pharmacology; D006168:Guinea Pigs; D007473:Ion Channels / Q000502:physiology*; D008274:Magnesium / Q000494:pharmacology; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000502:physiology*; D011957:Receptors, Opioid / Q000502:physiology
D007473:Ion Channels; D010879:Piperazines; D011759:Pyrrolidines; D011810:Quinoxalines; D016194:Receptors, N-Methyl-D-Aspartate; D011957:Receptors, Opioid; D016202:N-Methylaspartate; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; D008274:Magnesium; D005998:Glycine; D004298:Dopamine